FindTrial
Sign In

Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502512-36-00
Acronym
Xe-F-ILD-001
Enrollment
39
Registered
2023-03-06
Start date
2023-10-02
Completion date
Unknown
Last updated
2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Fibrosing Interstitial Lung Diseases

Brief summary

MR xenon ventilation and dissolved parameters, Worsening of pulmonary function test parameters, Worsening of HRCT parameters, Worsening in patient reported symptoms

Detailed description

Regionally decreased perfusion, Evidence of myocardial stran and fibrosis, Late contrast enhancement

Interventions

DRUGGadovist
DRUGinjektionsvæske
DRUGopløsning
DRUGHyperpolarised 129Xe 400 ml
DRUGHyperpolarised 129Xe 800 ml
DRUGHyperpolarised 129Xe 650 ml
DRUGHyperpolarised 129Xe 500 ml
DRUGHyperpolarised 129Xe gas 1000 ml

Sponsors

Aarhus University
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
MR xenon ventilation and dissolved parameters, Worsening of pulmonary function test parameters, Worsening of HRCT parameters, Worsening in patient reported symptoms—

Secondary

MeasureTime frame
Regionally decreased perfusion, Evidence of myocardial stran and fibrosis, Late contrast enhancement—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026